Literature DB >> 19626480

Parent-of-origin effect in transthyretin related amyloid polyneuropathy.

Bernard Bonaïti1, Flora Alarcon, Catherine Bonaïti-Pellié, Violaine Planté-Bordeneuve.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19626480     DOI: 10.1080/13506120903093944

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  6 in total

1.  Non-parametric estimation of survival in age-dependent genetic disease and application to the transthyretin-related hereditary amyloidosis.

Authors:  Flora Alarcon; Violaine Planté-Bordeneuve; Malin Olsson; Grégory Nuel
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

2.  TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?

Authors:  Bernard Bonaïti; Malin Olsson; Urban Hellman; Ole Suhr; Catherine Bonaïti-Pellié; Violaine Planté-Bordeneuve
Journal:  Eur J Hum Genet       Date:  2010-03-17       Impact factor: 4.246

3.  A Missense Variant p.Ala117Ser in the Transthyretin Gene of a Han Chinese Family with Familial Amyloid Polyneuropathy.

Authors:  Qian Chen; Lamei Yuan; Xiong Deng; Zhijian Yang; Shengwang Zhang; Sheng Deng; Hongwei Lu; Hao Deng
Journal:  Mol Neurobiol       Date:  2017-07-31       Impact factor: 5.590

Review 4.  Expanding the toolbox of ADHD genetics. How can we make sense of parent of origin effects in ADHD and related behavioral phenotypes?

Authors:  Tetyana Zayats; Stefan Johansson; Jan Haavik
Journal:  Behav Brain Funct       Date:  2015-10-16       Impact factor: 3.759

Review 5.  ATTR Epidemiology, Genetics, and Prognostic Factors.

Authors:  Chukwuemeka A Obi; William C Mostertz; Jan M Griffin; Daniel P Judge
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

Review 6.  Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.

Authors:  Marco Luigetti; Angela Romano; Andrea Di Paolantonio; Giulia Bisogni; Mario Sabatelli
Journal:  Ther Clin Risk Manag       Date:  2020-02-21       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.